Printer Friendly

NEORX SCIENTISTS ACHIEVE 1,000 PERCENT IMPROVED DELIVERY OF RADIOTHERAPY TO TUMORS IN ANIMAL STUDIES

 SEATTLE, April 2 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced that its scientists, using the company's proprietary pre-targeting technology, have achieved in an animal model a ten-fold improvement in delivery of radioactivity to tumor vs. blood as compared to conventionally administered radioimmunotherapy (RIT). As previously reported, they also reproduced rapid, complete regressions of chemotherapy-resistant human lung cancer tumors in the mice.
 "These results confirm our belief that NeoRx's pre-targeting technology is superior to conventionally administered radioimmunotherapy," said Paul G. Abrams, M.D., J.D., NeoRx president and CEO, and an oncologist. "In the company's recent presentation at the Eighth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, we predicted that this technology can produce results of this magnitude. We have, therefore, reached our pre-clinical goal of 10-fold improvement as projected last December at the Robertson, Stephens & Co. Ninth Annual Medical Conference. We believe this new method is broadly applicable to deliver a wide range of agents specifically to tumor and we intend to fully exploit these opportunities."
 In conventional RIT, the radioactivity accumulates gradually in the tumor and is gradually eliminated from the body. The potency of the injected activity is lost over this time due to physical decay of the radioisotope. By contrast, NeoRx's latest results demonstrate immediate uptake of the radioactivity into the tumor and very rapid disappearance of the non-tumor bound radiation from the body. Dose to tumor is a predictor of efficacy, while dose in the blood predicts safety.
 Previously, NeoRx has also demonstrated anti-tumor responses in patients whose tumors were resistant to chemotherapy in phase I trials using conventional RIT. "Thus, if the vast improvement in the efficacy/safety ratio caused by pre-targeting is reproducible in humans, it should provide even better anti-tumor effects than produced with conventional RIT and with negligible toxicity," said Dr. Abrams.
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA its OncoTrac(R) Small Cell Lung Cancer Imaging Product, and has completed a phase III trial for a non-small cell lung cancer imaging agent. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 4/2/93
 /CONTACT: Robert M. Littauer, vice president and chief financial officer of NeoRx, 206-286-2519; or Anthony J. Russo, Ph.D., or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU:

GK-SH -- NY010 -- 2393 04/02/93 09:12 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 2, 1993
Words:425
Previous Article:DIGITAL ANNOUNCES ITS INTENTION TO RELOCATE OPERATIONS FROM MAYNARD MILL COMPLEX; CORPORATE HEADQUARTERS STAFF WILL MOVE TO ANOTHER MAYNARD SITE
Next Article:RONALD C. OGNAR JOINS STRONG FUNDS
Topics:


Related Articles
NEORX AWARDED PATENT FOR IMPROVED RADIOLABELING COMPOUNDS FOR CANCER IMAGING AND THERAPY
NEORX ANNOUNCES ENHANCED TUMOR DOSE FROM PRE-TARGETING IN PRECLINICAL MODELS
NEORX DEMONSTRATES EFFICACY IN ANIMALS OF TWO THERAPEUTIC PRODUCT LINES
NEORX REPORTS PROMISING EARLY RESULTS IN AVICIDIN CANCER THERAPY STUDIES
A SINGLE DOSE OF NEORX'S AVICIDIN PRODUCES CURES IN PRECLINICAL ANIMAL MODELS
NEORX DRUG SHOWN TO INHIBIT RESTENOSIS IN A SWINE PRECLINICAL MODEL; SCIENTISTS PRESENT TWO STUDIES AT AMERICAN HEART ASSOCIATION CONFERENCE
NEORX'S AVICIDIN ADVANCES IN PHASE I II CANCER THERAPY TRIALS
A SINGLE DOSE OF NEORX'S AVICIDIN PRODUCES TUMOR REGRESSIONS IN EARLY PHASE I TRIALS; DOSE OPTIMIZATION AND ESCALATION TO CONTINUE
NeoRx Presents Phase I Avicidin(R) Data at ASCO
Proteins May Help Identify Patients Who Will Respond Better to Different Treatments in Certain Cancers.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters